| Filed On | Filing |
|---|---|
| 02 Oct 2026 |
Form 4: Sherman Darren, Director
Sold 15,000 shares ($95.4K) |
| 01 Oct 2026 | 144 |
| 01 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
330 patients randomized as of September 30, 2026, surpassing full trial enrollment target |
| 11 Sep 2026 |
Form 4: Hochman David P, Director
Gave up 3,283 shares to cover exercise price or tax ($19.1K) · Gave up 3,283 shares to cover exercise price or tax ($19.1K) |
| 08 Sep 2026 |
Form 4: Hochman David P, Director
Bought 10,000 shares ($47.9K) |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure
Accelerating high - impact technologies to patients through risk - reward sharing partnerships Corporate Overview | September 2026 Nasdaq : OBIO |
| 02 Sep 2026 |
Form 4: Sherman Darren, Director
Sold 15,000 shares ($74.1K) |
| 01 Sep 2026 | 144 |
| 28 Aug 2026 |
Form 4: Taylor Andrew Lawrence, Chief Financial Officer
Gave up 3,076 shares to cover exercise price or tax ($16.2K) |
| 28 Aug 2026 |
Form 4: Sherman Darren, Director
Gave up 4,925 shares to cover exercise price or tax ($25.9K) · Bought 2,000 shares ($10.7K) |
| 28 Aug 2026 |
Form 4: Aiello Joshua, Principal Accounting Officer
Gave up 203 shares to cover exercise price or tax ($1.07K) |
| 14 Aug 2026 |
Form 4: Pacitti David, Director
Gave up 3,761 shares to cover exercise price or tax ($16.6K) |
| 14 Aug 2026 |
Form 4: Fain Eric S, Director
Gave up 5,145 shares to cover exercise price or tax ($22.7K) |
| 14 Aug 2026 |
Form 4: Mack John Prosper, Director
Gave up 4,885 shares to cover exercise price or tax ($21.6K) |
| 14 Aug 2026 |
Form 4: Cleary Chris, Director
Gave up 4,238 shares to cover exercise price or tax ($18.7K) |
| 10 Aug 2026 | 10-Q |
| 04 Aug 2026 |
Form 4: Sherman Darren, Director
Sold 15,000 shares ($61.4K) |
| 03 Aug 2026 | 144 |
| 02 Jul 2026 |
Form 4: Sherman Darren, Director
Sold 15,000 shares ($64.1K) |
| 01 Jul 2026 | 144 |
Loading...
